What is King Pharmaceuticals's EV / sales?

King Pharmaceuticals (KG) reported EV / sales of 4.6× in Q1 2026.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

King Pharmaceuticals KG EV / sales

EV / sales at other companies

Arch Capital GroupACGL

1.8×-0.3×

Everest GroupEG

0.8×-0.1×

SiriusPointSPNT

0.7×0.0×

Skyward Specialty Insurance Group, Inc.SKWD

1.6×+0.2×

Selective Insurance GroupSIGI

1×-0.3×

Tiptree Inc.TIPT

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-67.6%

Enterprise value$184.93M-50.0%

P/E1.2×—

P/S1.6×-24.3×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Calculated from King Pharmaceuticals’s reported figures.

enterprise value/total revenue=4.6×

Based on the most recent quarter.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's EV / sales?: King Pharmaceuticals (KG) reported EV / sales of 4.6× in Q1 2026.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.